Each product is developed to meet a unique formulation challenge and is supported by research and data generated internally. Before launching, every excipient is tested to ensure a high safety profile and conformity to NF, EP, JP, and other well-recognized pharmacopoeia.
Since , for example, the company has been responsible for the completion of more than 25 NF and EP monographs. The company has a range of emulsifiers for one pot, cold process, and low-energy emulsification processes, also coded in innumerable products worldwide.
Transdermal is a route of administration wherein active ingredients are delivered across the skin for systemic distribution. Poroplastic — type systems. Jaikaria indicates that hormonal steroidal conditions, pain, urinary incontinence, erectile dysfunction, and smoking cessation are examples of the types of conditions that drugs using the platform can treat. Binary systems : Propylene glycol, oleic acid d. In particular, the research evaluated the potential for differences in therapeutic performance in situations where the PK profiles of a prospective generic methylphenidate TDS were evaluated using traditional PK endpoints of maximum concentration Cmax and area under the concentration-time curve AUC.
Characterization of topical formulations for sensory attributes feel, touch, spreadability, etc. Musakhanian adds. Selecting the right excipient s for the intended delivery system, relative to the type of active drug entity and its targeted therapy is likely to be the key step in saving time and cost to market. Invisicare delivers drugs on, in, or through the skin with a controlled release and can be tailored to almost any type of molecule.
Invisicare has multiple applications, including topical, transdermal, and mucosal in development. Invisicare is a filmforming complex of hydrophilic and hydrophobic polymers that are readily available and used in the marketplace. The formulations do not use alcohol, waxes, or other organic solvents and can be formulated into creams, lotions, sprays, or gels.
In , Skinvisible was granted two patents: a sunscreen avobenzone photostability patent for the US and a technology patent for Europe. Skinvisible now has 40 patented formulations with various indications, all available for licensing on an exclusive basis, including a recently developed formulation for Netherton syndrome for which the company is seeking orphan drug status in the US and Europe.
Providing innovative, patient friendly drug delivery devices is increasingly becoming a requirement, not an option, when introducing therapeutic products involving traditional needle and syringe use as evidenced by the prevalence of autoinjections, prefilled syringes, and pressure jet applicators offered by most large pharmaceutical companies today.
Although prefilled syringes, auto injectors, and pressure jet applicators products have improved patient convenience and compliance by reducing preparation and delivery steps, many patients still associate them with a needle experience.
Zosano Pharma aims for its ZP Patch formerly known as Macroflux to replace the syringe altogether in target compound areas in which the patient needs are the highest. Dry-coated drug on the thin microneedle patch allows for rapid delivery into the skin. The creation of pathways through the skin improves control of drug distribution throughout the patch treatment area, reduces the potential for skin irritation, and provides for efficient drug delivery and absorption.
The ZP patch has proven capable of delivering a broad range of compounds, including peptides, proteins, small molecules, and vaccines. Zosano Pharma has identified 10 key drugs that best fit the criteria for the initial product portfolio of the ZP patch.
Zosano will receive revenue-based royalties based on sales of the ZP patch formulation of Teribone in the Asian territories, as well as reimbursement for all development and manufacturing costs and commercialization. AKP is committing significant additional financial and technical resources toward the development of the patch for the treatment of osteoporosis in the Asian territories, and has already commenced clinical trials, which are now entering the pivotal Phase III stage.
Looking forward, the pros predict that future growth rate for transdermal, topical, and subcutaneous products will be slow to moderate. Seed,5 A. Johnston2 and C. Chik, A. Johnston, A.
Tucker, S. Chew, L. Johnston, K.
Kirby, A. Tucker and C. Adv Drug Deliv Rev. Routes of administration , dosage forms. Mouthwash Toothpaste Ointment Oral spray. Smoking device Dry-powder inhaler DPI. Oxygen mask and Nasal cannula Oxygen concentrator Anaesthetic machine Relative analgesia machine. Intradermal Subcutaneous Transdermal implant.
Intracavernous Intravitreal Intra-articular injection Transscleral. Intracerebral Intrathecal Epidural. Categories : Medical treatments Routes of administration.
Hidden categories: CS1 maint: multiple names: authors list Articles to be split from July All articles to be split. Namespaces Article Talk. Merkle HP.
Transdermal delivery systems. Methods Find Exp Clin Pharmacol ; Brown L and Langer R. Transdermal delivery of drugs. Annu Rev Med ; Transdermal drug delivery system: A review. Curr Pharma Res ; Flynn GL.
Percutaneous Absorption. Skin Deep. Eur J Pharm Biopharm ; Transdermal drug delivery systems with major emphasis on Transdermal Patches: A review. Aulton ME. Churchill Livingstone: Elsevier; Chien YW. Novel drug delivery systems, Drugs and the Pharmaceutical Sciences, Vol.
Sugibayashi K, Morimoto Y. Polymers for transdermal drug delivery systems. J Control Release ; Hadgraft J, Guy RH. Transdermal Drug Delivery. Transdermal drug delivery system and evaluation. Int J Adv Pharm Sci ; Adhesive interactions between polymers and skin in transdermal delivery systems.
Polym Mater: Sci Eng ; Design of a new water-soluble pressure-sensitive adhesive for patch preparation. Tyle P. Drug Delivery device. Permeation Enhancer compatible with transdermal drug delivery systems.